Allogene Therapeutics, Inc.ALLO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · allogene.com
Allogene Therapeutics, headquartered in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. It is developing a pipeline of off-the-shelf CAR T cell product candidates intended to deliver readily available cell therapy on-demand, more reliably and at greater scale.
Key ratios
FCF / Sales
-2211.2%TTM
2024
-914452.8%2023
-251785.3%
ROA
-26.8%2025
2024
-27.0%2023
-26.8%
ROE
-53.4%2025
2024
-55.1%2023
-55.5%
Revenue growth
-100.0%TTM
2024
-76.8%2023
-39.1%
Recent news
Track ALLO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer